These results suggest that, since sunitinib and gefitinib are competitive binders of ATP binding sites of protein kinases and their anticancer activities are related to and inversely proportional to iATP concentration, thus eATP could rescue their treated cancer cells by enhancing iATP levels through eATP internalization and therefore drug resistance. The gene discussed is WEE1; the disease is cancer.